Authors

Hongyun Huang, General Hospital of Armed Police Forces
Wise Young, State University of New Jersey
Lin Chen, Tsinghua University Yuquan Hospital
Shiqing Feng, Tianjin Medical University General Hospital
Ziad M. Zoubi, Al-Saif Medical Center
Hari Shanker Sharma, University Hospital
Hooshang Saberi, Tehran University of Medical Sciences
Gustavo A. Moviglia, Maimonides University
Xijing He, Second Affiliated Hospital of Xi’an Jiaotong University
Dafin F. Muresanu, University of Medicine and Pharmacy
Alok Sharma, LTM Medical College
Ali Otom, King Hussein Medical Centre-RJRC Amman
Russell J. Andrews, Nanotechnology & Smart Systems
Adeeb Al-Zoubi, University of Illinois
Andrey S. Bryukhovetskiy, NeuroVita Clinic of Interventional and Restorative Neurology and Therapy
Elena R. Chernykh, Institute of Fundamental and Clinical Immunology
Krystyna Domańska-Janik, Stem Cell Bioengineering Unit, Mossakowski Medical Research Centre
Emad Jafar, Al-Saif Medical Center
W. Eustace Johnson, Faculty of Medicine Dentistry and Life Sciences
Ying Li, UCL Institute of Neurology
Daqing Li, UCL Institute of Neurology
Zuo Luan, Navy General Hospital of PLA
Gengsheng Mao, General Hospital of Armed Police Forces
Ashok K. Shetty, Texas A&M Health Science Center
Dario Siniscalco, University of Campania
Stephen Skaper, University of Padua
Tiansheng Sun, PLA Army General Hospital
Yunliang Wang, 148th Hospital
Lars Wiklund, Umea University
Qun Xue, Hospital of Soochow University
Si-Wei You, Fourth Military Medical University
Zuncheng Zheng, The Central Hospital of Taian
Milan R. Dimitrijevic, Baylor College of Medicine
W. S. Masri, Robert Jones and Agnes Hunt Orthopaedic Hospital
Paul R. Sanberg, University of South FloridaFollow
Qunyuan Xu, Capital Medical University
Guoming Luan, Capital Medical University
Michael Chopp, Henry Ford Health System
Kyoung-Suok Cho, The Catholic University of Korea
Xin-Fu Zhou, University of South Australia
Ping Wu, University of Texas
Kai Liu, The Hong Kong University of Science and Technology
Hamid Mobasheri, University of Tehran
Seiji Ohtori, Chiba University
Hiroyuki Tanaka, Osaka University
Fabin Han, Liaocheng University/Liaocheng People’s Hospital
Yaping Feng, Kunming General Hospital of Chengdu Military Command of Chinese PLA
Shaocheng Zhang, The Second Military Medical University
Yingjie Lu, Chengde Dadu Hospital
Zhicheng Zhang, PLA Army General Hospital
Yaojian Rao, Luoyang Orthopedic Hospital of Henan Province
Zhouping Tang, Tongji Medical College of HUST
Haitao Xi, Beijing Rehabilitation Hospital of Capital Medical University
Liang Wu, Beijing Xiaotangshan Rehabilitation Hospital
Shunji Shen, Weihai Municipal Hospital
Mengzhou Xue, The Second Affiliated Hospital of Zhengzhou University
Guanghong Xiang, The Second Affiliated Hospital of Zhengzhou University
Xiaoling Guo, PLA Army 266 Hospital
Xiaofeng Yang, The First Affiliated Hospital of Zhejiang University Medical College
Yujun Hao, The First Affiliated Hospital of Xinjiang Medical University
Yong Hu, The University of Hong Kong
Jinfeng Li, Umea University
Qiang AO, China Medical University
Bin Wang, The Second Affiliated Hospital of Guangzhou Medical University
Zhiwen Zhang, First Affiliated Hospital of Chinese PLA General Hospital
Ming Lu, Second Affiliated Hospital of Hunan Normal University
Tong Li, The Second Affiliated Hospital of Xinxiang Medical University

Document Type

Article

Publication Date

2022

Keywords

cell therapy, neurorestoration, clinical application guideline neurorestoratology

Abstract

Cell therapy has been shown to be a key clinical therapeutic option for central nervous system diseases or damage. Standardization of clinical cell therapy procedures is an important task for professional associations devoted to cell therapy. The Chinese Branch of the International Association of Neurorestoratology (IANR) completed the first set of guidelines governing the clinical application of neurorestoration in 2011. The IANR and the Chinese Association of Neurorestoratology (CANR) collaborated to propose the current version “Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017)”. The IANR council board members and CANR committee members approved this proposal on September 1, 2016, and recommend it to clinical practitioners of cellular therapy. These guidelines include items of cell type nomenclature, cell quality control, minimal suggested cell doses, patient-informed consent, indications for undergoing cell therapy, contraindications for undergoing cell therapy, documentation of procedure and therapy, safety evaluation, efficacy evaluation, policy of repeated treatments, do not charge patients for unproven therapies, basic principles of cell therapy, and publishing responsibility.

Digital Object Identifier (DOI)

https://doi.org/10.1177/0963689717746999

Rights Information

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

Citation / Publisher Attribution

Cell Transplantation, v. 27, issue 2, p. 310-324

Was this content written or created while at USF?

Yes

Included in

Neurosurgery Commons

Share

COinS